Immunic Inc (IMUX) Stock: What the Analysts are Saying

The stock has a 36-month beta value of 1.94. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for IMUX is 83.16M, and at present, short sellers hold a 2.98% of that float. On April 03, 2024, the average trading volume of IMUX was 1.01M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

IMUX) stock’s latest price update

Immunic Inc (NASDAQ: IMUX)’s stock price has gone decline by -10.29 in comparison to its previous close of 1.36, however, the company has experienced a -6.15% decrease in its stock price over the last five trading days. Proactive Investors reported 2024-03-20 that Immunic Inc (NASDAQ:IMUX) has received a Notice of Allowance for a composition-of-matter patent covering a specific polymorph of vidofludimus calcium, which is being advanced as a treatment for chronic inflammatory and autoimmune diseases, particularly multiple sclerosis. The patent, titled “Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents”, solidifies the company’s intellectual property protection around its lead, late-stage asset.

IMUX’s Market Performance

Immunic Inc (IMUX) has seen a -6.15% fall in stock performance for the week, with a -15.86% decline in the past month and a -18.67% plunge in the past quarter. The volatility ratio for the week is 6.08%, and the volatility levels for the past 30 days are at 6.78% for IMUX. The simple moving average for the past 20 days is -11.11% for IMUX’s stock, with a -18.66% simple moving average for the past 200 days.

Analysts’ Opinion of IMUX

Many brokerage firms have already submitted their reports for IMUX stocks, with SVB Leerink repeating the rating for IMUX by listing it as a “Mkt Perform.” The predicted price for IMUX in the upcoming period, according to SVB Leerink is $5 based on the research report published on October 21, 2022 of the previous year 2022.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see IMUX reach a price target of $26. The rating they have provided for IMUX stocks is “Buy” according to the report published on September 19th, 2022.

Aegis Capital gave a rating of “Buy” to IMUX, setting the target price at $55 in the report published on April 15th of the previous year.

IMUX Trading at -5.81% from the 50-Day Moving Average

After a stumble in the market that brought IMUX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.77% of loss for the given period.

Volatility was left at 6.78%, however, over the last 30 days, the volatility rate increased by 6.08%, as shares sank -20.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.55% upper at present.

During the last 5 trading sessions, IMUX fell by -6.15%, which changed the moving average for the period of 200-days by -26.73% in comparison to the 20-day moving average, which settled at $1.3570. In addition, Immunic Inc saw -18.67% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at IMUX starting from Whaley Glenn, who purchase 5,000 shares at the price of $1.75 back on May 15 ’23. After this action, Whaley Glenn now owns 25,510 shares of Immunic Inc, valued at $8,750 using the latest closing price.

Stock Fundamentals for IMUX

The total capital return value is set at -3.36. Equity return is now at value -131.28, with -102.84 for asset returns.

Based on Immunic Inc (IMUX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -53.09.

Currently, EBITDA for the company is -99.11 million with net debt to EBITDA at 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.12.

Conclusion

To sum up, Immunic Inc (IMUX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts